STOCK TITAN

Actinium Pharmaceuticals, Inc. - $ATNM STOCK NEWS

Welcome to our dedicated page for Actinium Pharmaceuticals news (Ticker: $ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Actinium Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Actinium Pharmaceuticals's position in the market.

Rhea-AI Summary

Actinium Pharmaceuticals will host a KOL webinar on May 20, 2024, at 8:00 AM ET to discuss the Iomab-ACT commercial CAR T-cell therapy trial being conducted at the University of Texas Southwestern (UTSW). Dr. Farrukh Awan, an expert in leukemia and lymphoma treatment, will join as the principal investigator. Iomab-ACT, an ARC targeting CD45, aims to replace non-targeted chemotherapy in conditioning prior to cell and gene therapies. Phase 1 trial results showed no immune effector cell-associated neurotoxicity syndrome (ICANS) in treated patients and minimal Cytokine Release Syndrome (CRS). The CAR-T market, projected to grow at an 11% CAGR, presents a significant opportunity for Iomab-ACT, which targets an addressable patient population expected to reach 93,000 in the U.S. by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
conferences
-
Rhea-AI Summary

Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients with relapsed or refractory acute myeloid leukemia (r/r AML) receiving an Iomab-B led bone marrow transplant (BMT). Patients with TP53 mutations saw a median overall survival of 5.49 months compared to 1.66 months for those not receiving Iomab-B. The trial enrolled high-risk patients and showed 92% 1-year survival and 69% 2-year survival rates in those receiving Iomab-B led BMT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary

Actinium Pharmaceuticals announced that multiple abstracts highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A, along with novel linker technology for solid tumors, have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting. The abstracts feature improved survival with both Iomab-B and Actimab-A in high-risk acute myeloid leukemia patients, including TP53 mutations. Actinium's presence at the SNMMI showcases its leadership in developing ARCs, with a focus on targeted radiotherapy for blood cancers and solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
Rhea-AI Summary

Actinium Pharmaceuticals, Inc. announced a KOL webinar to discuss its Iomab-ACT trial with a leading FDA approved CAR T-cell therapy at the University of Texas Southwestern. The webinar will highlight the potential billion-dollar market opportunity in lymphodepletion. Dr. Farrukh Awan will lead the trial, aiming to study Iomab-ACT with an FDA approved CAR-T cell therapy for the first time. The company presented positive phase 1 trial results at the Tandem Meetings, showing promising safety and efficacy profiles. With the expanding CAR-T market and the need for improved conditioning in cellular therapy, Iomab-ACT presents a revenue opportunity in line with the growing patient population for cell and gene therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B at the European Bone Marrow Transplant Annual Meeting, showing higher remission rates and durable complete remission in patients with active relapsed or refractory acute myeloid leukemia. The study revealed a median overall survival of 5.49 months in TP53 positive patients receiving Iomab-B, compared to 1.66 months in those who did not receive it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
-
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces positive Phase 3 SIERRA trial results for Iomab-B in patients with TP53 mutation at the European Bone Marrow Transplant Society meeting. The trial showed high statistical significance in achieving durable Complete Remission and 100% BMT access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.32%
Tags
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces a potential breakthrough in targeted radiotherapy conditioning with Iomab-ACT, aiming to replace non-targeted chemotherapy in cell and gene therapies. The collaboration with UT Southwestern for a clinical trial on CAR T-cell therapy shows promising results in reducing toxicities like ICANS and CRS. Iomab-ACT presents a significant market opportunity in the growing field of cellular and gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
-
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces a strategic initiative to manufacture Actinium-225 using a proprietary cyclotron-based method. The company's technology is supported by 5 U.S. patents, 49 international patents, and significant technical expertise. Actinium-225 produced by this method is highly pure, cost-effective, and has higher yields. The initiative includes a multi-million-dollar investment to scale up production to meet growing demand. Actinium aims to collaborate globally to maximize the value of its patents and capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.54%
Tags
none
-
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. reports positive Phase 3 SIERRA trial results for Iomab-B in treating r/r AML patients 65+ years at TCT Meetings. Unprecedented 100% BMT access and engraftment with improved long-term survival outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.14%
Tags
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) highlighted positive results from the Phase 3 SIERRA trial of Iomab-B, showing significant improvements in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B. The trial demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation, leading to complete remissions in over 50% of patients. The company also presented promising data on radiopharmaceutical dosimetry and early results from a Phase 1 study using Iomab-ACT conditioning with CD19 CAR-T therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
Actinium Pharmaceuticals, Inc.

NYSE:ATNM

ATNM Rankings

ATNM Stock Data

253.16M
28.61M
2.16%
24.57%
7.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About ATNM

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o